Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
Low dose isotretinoin 0.3 mg/kg leads to higher participant‐assessed improvement in rosacea severity1 Good to… compared with doxycycline 50‐100 mg (high certainty).
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Low dose isotretinoin 0.3 mg/kg showed no clear difference in proportion of participants with adverse event compared with doxycycline 50‐100 mg (high certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
Low dose isotretinoin 0.3 mg/kg leads to higher physician‐assessed improvement in rosacea severity1 Complete… compared with doxycycline 50‐100 mg (high certainty).
1 finding from 1 review
Assessment of erythema or telangiectasia Improved or healed · Participants with rosacea
Low dose isotretinoin 0.3 mg/kg showed no clear difference in assessment of erythema or telangiectasia Improved or healed compared with doxycycline 50‐100 mg (high certainty).
1 finding from 1 review
Lesion count1 · Participants with rosacea
1 finding from 1 review
Time needed until improvement ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event1 Pain as assessed by VAS (0 to 10; higher score is worse) · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Assessment of erythema or telangiectasia1 Spectrophotometer to assess facial redness · Participants with rosacea
1 finding from 1 review
Lesion count ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Time needed until improvement ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review